Cannabinoid treatment for autism: a proof-of-concept randomized trial

BACKGROUND: Endocannabinoid dysfunction in animal models of autism spectrum disorder (ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this placebo-controlled double-blind comparison of two oral cannabinoid solutions in 150 participants (age 5–21 years) with ASD. ME...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mol Autism
Glavni autori: Aran, Adi, Harel, Moria, Cassuto, Hanoch, Polyansky, Lola, Schnapp, Aviad, Wattad, Nadia, Shmueli, Dorit, Golan, Daphna, Castellanos, F. Xavier
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2021
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7860205/
https://ncbi.nlm.nih.gov/pubmed/33536055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13229-021-00420-2
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items